Lazard Asset Management
KRYS icon

Lazard Asset Management’s Krystal Biotech KRYS Stock Holding History

Lazard Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,058
Closed -$261K – 1987
2025
Q4 		$261K Buy
+1,058
New +$223K ﹤0.01% 1569
2025
Q3 		– Sell
-155
Closed -$21K – 2086
2025
Q2 		$21K Sell
155
-249
-62% -$36.6K ﹤0.01% 2119
2025
Q1 		$72K Sell
404
-72
-15% -$12.1K ﹤0.01% 1906
2024
Q4 		$74K Sell
476
-922
-66% -$164K ﹤0.01% 1890
2024
Q3 		$253K Sell
1,398
-26
-2% -$5.01K ﹤0.01% 1552
2024
Q2 		$259K Buy
1,424
+116
+9% +$19.5K ﹤0.01% 1474
2024
Q1 		$232K Buy
1,308
+282
+27% +$39.2K ﹤0.01% 1252
2023
Q4 		$125K Buy
1,026
+19
+2% +$2.11K ﹤0.01% 1570
2023
Q3 		$115K Buy
1,007
+294
+41% +$35.9K ﹤0.01% 1583
2023
Q2 		$82K Buy
713
+245
+52% +$25K ﹤0.01% 1653
2023
Q1 		$36K Buy
468
+100
+27% +$7.86K ﹤0.01% 1894
2022
Q4 		$28K Sell
368
-1,482
-80% -$110K ﹤0.01% 2055
2022
Q3 		$128K Buy
1,850
+6
+0.3% +$433 ﹤0.01% 1373
2022
Q2 		$120K Buy
1,844
+73
+4% +$4.54K ﹤0.01% 1450
2022
Q1 		$117K Buy
1,771
+499
+39% +$31.1K ﹤0.01% 1356
2021
Q4 		$88K Buy
1,272
+221
+21% +$12.9K ﹤0.01% 1489
2021
Q3 		$54K Sell
1,051
-522
-33% -$30.9K ﹤0.01% 1652
2021
Q2 		$106K Buy
1,573
+1,541
+4,816% +$108K ﹤0.01% 1325
2021
Q1 		$2K Hold
32
– – ﹤0.01% 1808
2020
Q4 		$1K Buy
+32
New +$1.6K ﹤0.01% 1819

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's KRYS Position: Q1 2026 in Review

Lazard Asset Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,058 shares — an estimated $261K sold.

Lazard Asset Management first reported a position in KRYS in Q4 2020 and held it in 20 quarters. The position peaked at $261K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Lazard Asset Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 1,058 Krystal Biotech shares in Q1 2026, an estimated $261K.
  • Lazard Asset Management first reported a position in Krystal Biotech in Q4 2020 and held it in 20 quarters.
  • Lazard Asset Management's Krystal Biotech position peaked at $261K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.